Xencor, Inc.
35
7
9
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 90/100
28.6%
10 terminated/withdrawn out of 35 trials
61.5%
-25.0% vs industry average
0%
0 trials in Phase 3/4
31%
5 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (35)
Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors
Role: lead
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
Role: lead
A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis
Role: lead
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Role: lead
Study of XmAb412 in Healthy Participants
Role: lead
Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis
Role: lead
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Role: lead
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Role: lead
A Study of XmAb23104 in People With Sarcoma
Role: collaborator
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Role: lead
Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic Dermatitis
Role: lead
XmAb20717 in Advanced Biliary Tract Cancers
Role: collaborator
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Role: collaborator
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
Role: lead
XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy
Role: collaborator
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
Role: lead
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Role: lead
A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors
Role: lead
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Role: lead
Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)
Role: lead